Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amarin Corp ADR (NQ: AMRN )

1.590 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 5, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,166
Open 1.590
Bid (Size) 1.560 (2)
Ask (Size) 1.620 (11)
Prev. Close 1.590
Today's Range 1.590 - 1.590
52wk Range 1.110 - 5.970
Shares Outstanding 396,940,908
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday. 
Via Benzinga
Sarissa Capital Intends to Vote “Abstain” at the Amarin Annual Meeting
From Sarissa Capital Management LP
Via Business Wire

Performance

YTD
-54.70%
-54.70%
1 Month
-3.05%
-3.05%
3 Month
-56.32%
-56.32%
6 Month
-54.05%
-54.05%
1 Year
-62.50%
-62.50%

More News

Read More
Amarin Outlines $100M Cost Saving Plan
Via Benzinga
Recap: Amarin Corp Q1 Earnings
Via Benzinga
Earnings Scheduled For March 1, 2022
Via Benzinga
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
Via Benzinga
Looking Into Amarin Corp's Return On Capital Employed
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022
Via Benzinga
A Peek Into The Markets: US Stock Futures Down; Jobs Report In Focus
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022
Via Benzinga
10 Biggest Price Target Changes For Thursday
Via Benzinga
81 Biggest Movers From Yesterday
Via Benzinga
Mid-Afternoon Market Update: Crude Oil Jumps 5%; Fed Boosts Interest Rates By 0.5%
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Mid-Day Market Update: Dow Rises 100 Points; Lyft Shares Plummet
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Nasdaq Tumbles 100 Points
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Amarin Corp's Earnings: A Preview
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Via Benzinga
NASDAQ:AMRN Long Term Investor Notice: Investigation of Potential Wrongdoing at Amarin Corporation Plc
Via SBWire
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
Via Benzinga
Lower Vascepa Volume Hits Amarin's Q4 Topline Growth
Via Benzinga
Amarin: Q4 Earnings Insights
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.